Previous 10 | Next 10 |
2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...
2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...
2023-08-24 07:41:04 ET Summary Akero Therapeutics is a biopharmaceutical company focused on developing therapies for nonalcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease that can lead to liver failure and other serious health complication...
2023-08-14 16:31:43 ET UBS has initiated coverage of Cymabay Therapeutics ( NASDAQ: CBAY ) with a buy rating, stating it sees a Phase 3 study for the company’s drug seladelpar in the treatment of primary biliary cholangitis, or PBC, yielding positive data. UBS said it exp...
2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...
2023-08-03 18:45:41 ET Summary Intercept Pharmaceuticals' Q2 earnings reveal 17% growth in revenue and focus on Ocaliva for treating PBC, discontinuing NASH development. Despite strong revenue growth and promising Ocaliva expansion, concerns include substantial debt and lingering ...
2023-08-02 11:28:05 ET Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President and CEO Andrew Saik - Chief Financial Of...
2023-08-02 07:06:46 ET Intercept Pharma press release ( NASDAQ: ICPT ): Q2 GAAP EPS of -$0.14 beats by $0.38 . Revenue of $83.72M (+16.7% Y/Y) beats by $4.15M. As of June 30, 2023, Intercept had cash, cash equivalents, restricted cash, and investment debt secur...
Ocaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarter Company updates full-year 2023 Ocaliva net sales guidance to $320 million to $340 million; reiterates non-GAAP adjusted operating expense guidance of $350 million to $...
2023-08-01 11:17:37 ET Intercept Pharma ( NASDAQ: ICPT ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.46 (+32.4% Y/Y) and the consensus Revenue Estimate is $79.57M (+10.9% Y/Y). Over the la...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...